CONTENTS:
- The Brazilian 'Cracolândia' open drug scene and the challenge of implementing a comprehensive and effective drug policy [Editorial]. Ribeiro M., Duailibi S., Frajzinger R., Alonso A.L.S., Marchetti L., Williams A.V., et al., p. 571-573.
- Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures? [For debate]. Strang J., McDonald R., Tas B., Day E., p. 574-582.
- Tangled-up and blue: releasing the regulatory chokehold on take-home naloxone. Winstanley E.L., p. 583-584.
- Intranasal naloxone soon to become part of evolving clinical practice around opioid overdose prevention. Dietze P., Cantwell K., p. 584-586.
- Radical red tape reduction by government supported nasal naloxone: the Norwegian pilot project is innovative, safe and an important contribution to further development and dissemination of take-home naloxone. Lobmaier P.P., Clausen T., p. 586-587.
- Ethical issues and stakeholders matter. Dale O., p. 587-589.
- Ensure global access to naloxone for opioid overdose management. Balster R.L., Walsh S.L., p. 589-590.
- New approved nasal naloxone welcome, but unlicensed improvised naloxone spray kits remain a concern: proper scientific study must accompany innovation. Strang J., McDonald R., p. 590-592.
- Gambling and gambling policy in Norway - an exceptional case. Rossow I., Hansen M.B., p. 593-598.
- Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis. Roberts E., Eden Evins A., McNeill A., Robson D., p. 599-612.
- Commentary on Roberts et al. (2016): Bupropion and varenicline are efficacious and well-tolerated cessation medications for smokers with serious mental illness. Prochaska J.J., p. 613-614.
- Respiratory sinus arrhythmia as a potential measure in substance use treatment-outcome studies. Price C.J., Crowell S.E., p. 615-625.
- Temporal changes in alcohol-related mortality and morbidity in Australia. Ogeil R.P., Gao C.X., Rehm J., Gmel G., Lloyd B., p. 626-634.
- Commentary on Ogeil et al. (2016): Explaining increased alcohol-related harm and stable per capita consumption in Australia. Hall W.D., Chan G., p. 635-636.
- Relation between age of first drinking and mental health and alcohol and drug disorders in adulthood: evidence from a 35-year cohort study. Newton-Howes G., Boden J.M., p. 637-644.
- Population trends in smoking, alcohol use and primary prevention variables among adolescents in Iceland, 1997-2014. Kristjansson A.L., Sigfusdottir I.D., Thorlindsson T., Mann M.J., Sigfusson J., Allegrante J.P., p. 645-652.
- The burden of disease attributable to cannabis use in Canada in 2012. Imtiaz S., Shield K.D., Roerecke M., Cheng J., Popova S., Kurdyak P., et al., p. 653-662.
- Commentary on Imtiaz et al. (2016): The burden of disease attributable to cannabis - implications for policy. Hall W.D., p. 663-664.
- Qualitative evaluation of a novel contingency management-related intervention for patients receiving supervised injectable opioid treatment. Neale J., Tompkins C.N.E., Strang J., p. 665-674.
- Measuring benefits of opioid misuse treatment for economic evaluation: health-related quality of life of opioid-dependent individuals and their spouses as assessed by a sample of the US population. Wittenberg E., Bray J.W., Aden B., Gebremariam A., Nosyk B., Schackman B.R., p. 675-684.
- Advancing patient-centered care for structurally vulnerable drug-using populations: a qualitative study of the perspectives of people who use drugs regarding the potential integration of harm reduction interventions into hospitals. McNeil R., Kerr T., Pauly B., Wood E., Small W., p. 685-694.
- Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Hser Y.-I., Evans E., Huang D., Weiss R., Saxon A., Carroll K.M., et al., p. 695-705.
- Awareness and use of electronic cigarettes and heat-not-burn tobacco products in Japan. Tabuchi T., Kiyohara K., Hoshino T., Bekki K., Inaba Y., Kunugita N., p. 706-713.
- Integrating smoking cessation into routine care in hospitals - a randomized controlled trial. Thomas D., Abramson M.J., Bonevski B., Taylor S., Poole S.G., Paul E., et al., p. 714-723.
- Characteristics of users and usage of different types of electronic cigarettes: findings from an online survey. Etter J.-F., p. 724-733.
- The effect of potential electronic nicotine delivery system regulations on nicotine product selection. Pesko M.F., Kenkel D.S., Wang H., Hughes J.M., p. 734-744.
- Liquor licensing or confounding events? Further questions about the interpretations of Menéndez et al. (2015). Humphreys D.K., p. 745-746.
- A response to Dr Humphreys. Weatherburn D., p. 746-747.
- Tobacco control research: a tale of two Delphi groups. McKeganey N., Russell C., p. 747-748.
- Is Captagon (fenethylline) helping to fuel the Syrian conflict? Van Hout M.C., Wells J., p. 748-749.